Catalogus

Kies je taal
Phones:
E-mail
hello@peptideseuro.com
We are on social networks
Go to contacts
0 0
Established

Tirzepatide

GLP-1/GIP Receptor Agonist Peptide

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has become one of the most studied peptides in modern metabolic research. It simultaneously targets two incretin pathways, making it a subject of intense scientific interest for its role in glucose metabolism and body composition. Researchers continue to investigate its unique dual mechanism, which distinguishes it from single-agonist compounds.

Aliases: GIP/GLP-1 dual agonist, Mounjaro, Zepbound

Research score
10/10

Key fact

First dual GIP/GLP-1 receptor agonist. Up to 22.5% body weight loss in Phase 3 trials (SURMOUNT-1). FDA-approved as Mounjaro and Zepbound.

Mechanism

Tirzepatide is a 39-amino acid acylated peptide with a C20 fatty diacid moiety enabling once-weekly dosing. It acts as an imbalanced dual agonist: full potency at the GIP receptor (equal affinity to native GIP) and approximately 5-fold weaker affinity at the GLP-1 receptor vs native GLP-1. This imbalanced pharmacology drives unique signaling bias. Activates cAMP accumulation through both GIPR and GLP-1R, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing food intake via central appetite circuits.

Evidence note

Established — Robust Phase 3 data (SURPASS 1-5, SURMOUNT 1-4), FDA-approved as Mounjaro (T2D) and Zepbound (obesity). Thousands of participants across RCTs.

Studies

  • The Role of Tirzepatide in Management of T2D: SURPASS Trials

    39-amino acid synthetic peptide; dose-dependent weight loss up to 12.4%

    Open source · PMID 33325008

  • Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for T2D

    First dual agonist approved; superior HbA1c and weight reduction vs semaglutide

    Open source · PMID 36050763

  • Tirzepatide for obesity in adults without diabetes

    Up to 22.5% body weight loss at 15mg dose over 72 weeks

    Open source · PMID 37385275

FAQ

What happens when you stop taking it?

Clinical data shows weight regain in approximately 82% of participants after discontinuation. Most researchers view it as an ongoing protocol rather than a short cycle.

Is tirzepatide the same as Mounjaro?

Tirzepatide is the active compound. Mounjaro is the brand name for type 2 diabetes, Zepbound for obesity. Research-grade tirzepatide is the same molecule.

How does tirzepatide compare to semaglutide?

Tirzepatide is a dual agonist (GIP + GLP-1) while semaglutide targets only GLP-1. Clinical trials show tirzepatide produces roughly 50% more weight loss. It also tends to have a different side effect profile.

For research and educational use only. This content is not medical advice.